Ming-Shan Cai
Peng Liao1
Liang Jin
Hong-Wei Wang
Yong-Jun Chen- 1Department of Neurology, The Affiliated Nanhua Hospital, Hengyang Medical School, University of South China, Hengyang, China
- 2Department of Brain Function and Neuroelectrophysiology, The Affiliated Nanhua Hospital, Hengyang Medical School, University of South China, Hengyang, China
- 3Department of Neurology, The First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, China
Epilepsy is a common chronic disorder of the central nervous system characterized by recurrent seizures arising from abnormal, hypersynchronous neuronal activity; its pathogenesis is complex and remains incompletely understood. Hyperpolarization-activated cyclic nucleotide-gated (HCN) channels are a family of voltage-gated ion channels that mediate the hyperpolarization-activated cation current (Ih) and play key roles in regulating neuronal excitability, rhythmic activity, and synaptic transmission. Recent studies indicate that abnormal HCN channel expression, pathogenic genetic variants, or dysregulated protein interactions are closely linked to the onset and progression of epilepsy and may contribute to disease by destabilizing membrane-potential homeostasis, perturbing neurotransmitter balance, and disrupting network-level control of excitability. This review summarizes the structural and functional properties of HCN channels and focuses on their mechanistic roles in epileptogenesis, with the goal of informing clinical diagnosis and therapeutic development.
1 Introduction
Epilepsy is one of the most common neurological disorders worldwide, affecting approximately 50 million people, with a disproportionate burden in low- and middle-income countries (1). Despite antiseizure medications (ASMs) being the mainstay of therapy, about one-third of patients continue to have seizures and meet criteria for drug-resistant epilepsy (DRE) (2, 3). Beyond recurrent seizures, epilepsy is closely associated with cognitive impairment, reduced quality of life, and limitations in social participation (4). Etiologies are heterogeneous and, under the ILAE framework, include structural, genetic, infectious, metabolic, immune, and unknown causes (5). The contribution of genetics is increasingly recognized across epilepsy types: large-scale exome studies and recent reviews show that rare/ultra-rare and common variants jointly contribute to risk, with significant enrichment in pathways governing synaptic transmission and neuronal excitability (6–8). Among these, ion channels—core regulators of electrical signaling—occupy a central position; multiple channelopathies have been shown to directly cause epilepsy or profoundly influence seizure threshold and treatment response (7–9).
Among ion channels, HCN channels—by virtue of their unique hyperpolarization-activated gating and precise regulation of neuronal rhythmicity and excitability—have become a major research focus in epilepsy (10–12). HCN channels were first identified in cardiac sinoatrial nodal cells (13), where they mediate the “pacemaker current”—a current originally named for its role in generating intrinsic rhythmic activity that sustains cardiac rhythm (14, 15). Notably, while the “pacemaker” terminology originates from cardiac physiology, HCN channels in the central nervous system (CNS) do not typically serve a direct pacemaker function; instead, they primarily regulate neuronal rhythmicity and synchronization, which are critical for maintaining network stability. Subsequent studies demonstrated their broad distribution throughout the CNS, with particularly high expression in seizure-relevant regions such as the hippocampus, cerebral cortex, and thalamus (16–18). By carrying the hyperpolarization-activated cation current (Ih), HCN channels regulate the resting membrane potential, action potential firing rate, and presynaptic neurotransmitter release, thereby directly shaping neuronal excitability and network stability (19, 20).
2 Structure and functional properties of HCN channels
2.1 Molecular architecture and tissue distribution
HCN channels are specialized members of the voltage-gated ion-channel superfamily (Figure 1). Each functional channel is a tetramer of homologous subunits; every subunit contains six transmembrane segments (S1–S6) (21), a pore-forming region between S5 and S6 that confers ion selectivity (22, 23), and an intracellular C-terminal cyclic nucleotide-binding domain (CNBD) of ~120 amino acids (24, 25). The CNBD is a key regulatory module that binds cyclic nucleotides—cyclic adenosine monophosphate (cAMP) or cyclic guanosine monophosphate (cGMP)—and modulates channel gating via conformational coupling (21, 23, 26–29). Upon cAMP binding, channel open probability increases and the activation curve of the Ih current shifts toward more depolarized potentials, thereby enhancing channel responsiveness to hyperpolarizing stimuli (27, 30).
Figure 1. HCN channel subunit. It comprises six transmembrane segments (S1–S6). The S4 segment contains positively charged residues, serving as the voltage-sensing domain. At the proximal carboxyl (COOH) terminus, a C-Linker links to the cyclic nucleotide-binding domain (CNBD), which interacts with cyclic adenosine monophosphate (cAMP) to mediate channel regulation. The extracellular and intracellular compartments are indicated. NH₂ represents the amino terminus.
At the protein level, the mammalian HCN channel family comprises four isoforms (HCN1-HCN4) (22). Although these isoforms share ~60–80% amino-acid identity, they differ substantially in regional distribution, biophysical properties, and modes of regulation (25). In the CNS, HCN1 and HCN2 are the predominant isoforms: HCN1 is widely expressed in neocortex, hippocampus (especially CA1 pyramidal neurons and dentate granule cells), cerebellar Purkinje cells, and thalamic neurons; it activates most rapidly and is the least sensitive to cAMP, thereby contributing to rapid control of neuronal excitability (21, 31–34). HCN2 is broadly distributed across the CNS—with particularly high expression in the thalamus—activates more slowly, and exhibits greater cAMP sensitivity, making it more susceptible to intracellular signaling pathways (21, 33, 35, 36). By contrast, HCN3 and HCN4 show lower expression levels in the CNS; HCN4 is enriched in regions such as the hypothalamus and olfactory bulb (36, 37). This isoform-specific topography provides the structural basis for precise, region- and process-dependent modulation of neuronal activity by HCN channels.
2.2 Electrophysiological functions and physiological roles
The defining electrophysiological feature of HCN channels is hyperpolarization-activated gating: channels open when the membrane potential becomes more negative and conduct the Ih current (32, 38). Ih is a nonselective cation current that primarily carries Na+ influx and K+ efflux (38, 39); because Na+ entry predominates under physiological conditions, its net effect is to depolarize the membrane from hyperpolarized potentials—a depolarizing rebound (40, 41). On this basis, HCN channels exert a nuanced, bidirectional control over excitability and membrane stability. On the one hand, Ih-mediated rebound limits excessive hyperpolarization (e.g., following inhibitory postsynaptic potentials, IPSPs), accelerates the return of the membrane potential toward spike threshold, and under certain conditions can lower the excitability threshold (42, 43). On the other hand, channel opening markedly reduces neuronal input resistance, producing a shunt that attenuates synaptic currents and dampens excitatory drive (44). The net impact of Ih on excitability thus reflects the balance between these opposing actions and depends critically on channel density, isoform composition, and subcellular distribution (e.g., soma versus dendrites) (45, 46).
HCN channel-mediated Ih constitutes an important pacemaker-like depolarizing drive in neurons of rhythm-generating structures such as the thalamus and selected brainstem nuclei, contributing to the setting of resting membrane potential, input resistance, and intrinsic rhythmicity (47–51). In thalamic relay neurons, Ih acts in concert with T-type Ca2+ channels to determine subthreshold oscillatory properties (52); tuning the strength of Ih modulates membrane-potential oscillations and synchrony within the δ/θ bands, a mechanism tightly linked to thalamo-cortical rhythms across sleep–wake states and to state-dependent modulation of cognition (53). In the hippocampus, HCN channels likewise participate in θ rhythms and the temporal organization of information encoding; HCN1 is particularly enriched in dendrites and constrains spatiotemporal integration by shaping dendritic rectification and shunt properties (44, 54). At the dendritic level, increasing HCN1/Ih typically lowers input resistance, accelerates the decay of excitatory postsynaptic potentials (EPSPs), and weakens temporal summation; conversely, downregulating Ih prolongs EPSPs and facilitates the propagation of excitatory signals (44). In addition, HCN channels are present at presynaptic terminals and regulate transmitter release via multiple mechanisms: (i) through their Na+ permeability, they help set terminal membrane potential and Na+ homeostasis, potentially influencing vesicular loading and quantal size (55); and (ii) by coupling to low-threshold Ca2+ channels (e.g., CaV3.2), they restrict or tune Ca2+ entry, bidirectionally altering the release probability of glutamate or GABA (56, 57). Notably, the impact of HCN channels on presynaptic release is circuit- and terminal-type dependent: in some pathways HCN limits Ca2+ influx and constrains transmitter output (56, 57), whereas in others its depolarizing action can promote excitatory transmission (58). Together, these cellular and circuit mechanisms account for the bidirectional influence of HCN/Ih on physiological rhythms and on pathological activity such as epileptiform discharges (44, 49, 54, 59).
3 Mechanistic roles of HCN channels in epileptogenesis
3.1 Disruption of Ih due to altered HCN channel expression and function
A substantial body of evidence shows that epilepsy is associated with marked changes in HCN channel expression and/or function, resulting in abnormal Ih—arguably the most immediate mechanism by which HCN channels contribute to epileptogenesis (19, 60). Among these alterations, downregulation of HCN channels is the most frequently observed: within 1 week after status epilepticus (SE; acute phase), dendritic HCN expression in hippocampal CA1 pyramidal neurons begins to decline, accompanied by a hyperpolarizing shift in voltage-dependent activation; this downregulation progresses during the chronic phase of epilepsy (61). By contrast, in chemical models of chronic temporal lobe epilepsy (TLE) induced by kainate or pilocarpine—and in resected tissue from patients with TLE—dentate granule cells often exhibit increased Ih, which has been associated with elevated HCN1 and/or HCN4 expression, whereas HCN2 is unchanged in most studies; this pattern is commonly interpreted as a compensatory plasticity that may help limit granule-cell excitability (62).
The time course and regional profile of HCN/Ih remodeling are highly context dependent. In CA1 pyramidal neurons, SE triggers a rapid endocytosis and loss of HCN1, followed by decreases in protein and mRNA abundance and a hyperpolarizing shift in voltage-dependent activation—i.e., a gating reconfiguration (16). Mechanistically, reduced Ih does not drive the resting membrane potential toward spike threshold; more commonly it renders the membrane slightly more negative. However, because input resistance increases and temporal/spatial summation of EPSPs is enhanced, neurons become more responsive to excitatory inputs, yielding a net facilitation of network excitability. Conversely, augmenting HCN/Ih activity increases shunt and reduces dendritic integration, thereby lowering dendritic excitability (45). In epileptic tissue, phosphorylation-dependent downregulation of Ih gating constitutes an “acquired channelopathy”; pharmacologic reversal of these phosphorylation changes can restore gating and excitability (63). These adaptations are region- and isoform-specific: CA1 dendrites show the prototypical HCN1 downregulation/Ih reduction (16), whereas dentate granule cells more often display Ih upregulation (62); cortical changes are more variable and typically of smaller magnitude (64). By contrast, in models of absence epilepsy, Ih is often altered in ventrobasal thalamic neurons, and local HCN blockade can reduce or abolish spike–wave discharges (SWD) and absence seizures, underscoring the model-dependent bidirectionality of HCN-mediated effects (65).
3.2 Imbalanced interaction between HCN channels and neurotransmitter systems
Glutamate mediates excitatory transmission via AMPA/NMDA receptors, and its excessive activation is closely associated with Ca2+ overload, excitotoxicity, and epileptogenesis (66). Presynaptically, HCN channels exert bidirectional regulation on glutamate release: on the one hand, the opening of HCN1 channels in glutamatergic synaptic terminals targeting layer III pyramidal neurons in the mouse entorhinal cortex induces mild and sustained depolarization of the terminals, which inactivates low-threshold T-type Ca2+ channels (CaV3.2), reduces Ca2+ influx, and inhibits glutamate release; conversely, blocking HCN channels relieves this inhibitory effect and enhances glutamate release (56). On the other hand, the Na+ permeability of HCN channels increases the baseline Na+ level in terminals, promotes vesicular glutamate loading and quantal size, and thus facilitates glutamate release at certain synapses (e.g., cerebellar/brainstem giant synapses) (55). Postsynaptically, the cAMP/PKA signaling pathway can phosphorylate GluA1 at the Ser845 site, increasing the membrane expression and open probability of AMPA receptors. Several studies have indicated that inhibiting presynaptic HCN1 (accompanied by NMDAR inhibition) can enhance glutamate input and elevate the phosphorylation level/surface expression of GluA1, suggesting an indirect, cross-synaptic coupling between presynaptic HCN channel activity and postsynaptic AMPAR regulation (67).
HCN channels also remodel inhibitory transmission by acting on inhibitory interneurons and presynaptic mechanisms. By changing terminal membrane potential and Ca2+ entry, HCN activity can either facilitate or suppress GABA release in a circuit-dependent manner (57, 68). Under epileptic conditions, changes in HCN expression or function are therefore expected to modify the strength and dynamics of inhibitory output and to disturb the balance between excitatory and inhibitory neurotransmitter systems. The consequences of such alterations for neuronal excitability and network stability are further elaborated in Section 3.3.
3.3 Abnormal regulation of neuronal excitability and network stability by HCN channels
Epileptic seizures involve not only increased excitability of individual neurons but also abnormal synchronization of neural networks. The Ih current mediated by HCN channels participates in the maintenance of network stability by modulating membrane properties (resting membrane potential, input resistance, membrane time constant) and frequency resonance, thereby regulating the rhythmicity and synchronization propensity of neurons and networks (21, 37, 69). In the hippocampal network, HCN channels are particularly critical for the “excitatory-inhibitory (E-I) balance”: CA1 pyramidal neurons highly express HCN1 in their dendrites, and the Ih current can accelerate the decay of distal EPSPs, reduce temporal integration, and inhibit distal Ca2+ spikes, thereby limiting excessive excitation and synchronization (44, 45, 70). Inhibitory interneurons [e.g., parvalbumin-positive (PV+) basket cells] also express HCN/Ih channels; altering the Ih current affects their intrinsic excitability and presynaptic release, thereby shaping the inhibitory output onto pyramidal neurons (20, 71). Consistent with this, axon terminals of PV+ interneurons in the hippocampal CA1 region highly express HCN1, whose opening can enhance evoked GABA release, whereas pharmacological inhibition or genetic deletion of HCN1 reduces inhibitory output and destabilizes perisomatic inhibition (68). In contrast, in basket cells of layers 5–6 in the prefrontal cortex, HCN channels suppress GABA release by restricting presynaptic T-type Ca2+ influx, such that blocking HCN increases the frequency of miniature and spontaneous inhibitory postsynaptic currents (mIPSCs and sIPSCs) (57). These findings indicate that HCN-dependent control of GABA release provides a circuit- and region-specific mechanism for stabilizing or destabilizing inhibitory circuit output, and thus for tuning network stability.
In epilepsy/TLE models, the expression and surface localization of HCN1 in the dendrites of CA1 pyramidal neurons decrease rapidly, and the gating of Ih shifts toward more negative potentials (referred to as “acquired dendritic channelopathy”). This leads to increased input resistance, slowed decay of EPSPs, enhanced temporal integration, and ultimately elevated excitability and promoted synchronization of pyramidal neurons (16, 46). At the presynaptic level, HCN channels control presynaptic transmitter output/synaptic efficacy in a pathway-specific manner: in some inhibitory synapses, HCN activity limits GABA release via T-type Ca2+ channel coupling (57); whereas in the calyx of Held (a giant glutamatergic synapse) HCN-dependent Na+ influx increases quantal size and vesicular glutamate loading (55). Abnormal synchronization of firing and epileptogenicity can be increased not only in the hippocampus but also in cortical networks. For example, mice with selective reduction of HCN1 exhibit elevated cortical excitability and increased epileptogenicity, indicating a protective role of HCN1 (46). Taken together, HCN channels maintain E-I balance by simultaneously regulating the intrinsic excitability and presynaptic release of both pyramidal neurons and inhibitory interneurons. When HCN function undergoes spatiotemporally specific downregulation or mismatch, neural networks become more prone to abnormal synchronous firing, thereby triggering epilepsy (16, 21, 37, 69, 72).
4 Subtype-specific alterations of HCN channels in epilepsy
4.1 Temporal lobe epilepsy
TLE is the most common type of focal epilepsy in adults, accounting for a major proportion of cases undergoing surgical treatment. Its most prevalent pathological subtype is hippocampal sclerosis (HS). Recent methodological and review work has reinforced HS as the most common histopathological abnormality in drug-resistant TLE and has emphasized cohort-dependent variability in its reported frequency (73–75). Studies of resected human tissue and acquired epilepsy models demonstrate region-specific HCN remodeling in TLE. In the hippocampal CA1 region in MTLE-HS, HCN1 is commonly reduced at the transcript and/or protein level, with evidence for diminished dendritic expression; in acquired post-status epilepticus models, this loss of dendritic HCN1/Ih is accompanied by a hyperpolarizing shift in Ih voltage dependence, consistent with an “acquired dendritic h-channelopathy,” which can increase CA1 pyramidal-cell responsiveness by elevating input resistance and strengthening dendritic integration (16, 76, 77). In contrast, in dentate gyrus (DG) granule cells, multiple studies on human and rodent models of chronic TLE have shown that Ih density is commonly upregulated, consistent with increased expression of HCN1/HCN4 (HCN2 expression remains unchanged in most cases). This alteration is considered compensatory, as it helps restrict excessive excitation and spatiotemporal integration of DG (62, 78).
In chemical epileptogenic models, the time-course changes of HCN1 have been characterized: Rapid endocytosis and surface loss of dendritic HCN1 occur within hours to days after SE, followed by a decrease in protein levels and mRNA expression (16). Notably, these changes are particularly prominent in the hippocampal CA1 region and exhibit distinct regional differences along the dorsoventral axis, with more pronounced alterations in the dorsal CA1 compared to the ventral subdivision (77). Taken together, HCN remodeling in TLE is dependent on “brain region-subtype-time phase”: CA1 is dominated by HCN1 downregulation/Ih reduction (promoting excitation and epileptogenesis), while DG more frequently exhibits HCN/Ih upregulation (tendency toward compensation). This bidirectional plasticity, together with impaired network homeostasis, may contribute to epileptogenesis and the persistence of chronic epileptic networks (16, 75–78).
4.2 HCN channel genetic variants and epilepsy
4.2.1 HCN1 genetic variants and epilepsy
HCN1 is one of the key molecules mediating Ih in the central nervous system. De novo missense variants in HCN1 were first reported in 2014 as a cause of early infantile epileptic encephalopathy (EIEE)/developmental and epileptic encephalopathy (DEE), characterized by infantile onset, frequent drug resistance, and fever/heat sensitivity (19). Subsequent cohort studies have further expanded the variant spectrum and phenotypic heterogeneity, covering Dravet-like epilepsy and various types of refractory epilepsy in infants/children, and suggesting differences in drug responses (10). Functionally, HCN1 variants can exhibit bidirectional mechanisms: both gain-of-function (GOF) effects (e.g., causing voltage-dependent shifts, accelerated activation, and increased leak currents) and loss-of-function (LOF) effects (e.g., decreased current density), leading to imbalance in network excitation and rhythm (79). Corresponding knock-in mouse models directly confirm the pathogenicity of these variants and abnormal drug responses, providing a model basis for intervention strategies (80, 81). At the translational level, Org-34167, a brain-penetrant broad-spectrum HCN modulator, was recently shown in a study published in Epilepsia to correct the voltage dependence and leak currents of various HCN1-DEE variant channels. Additionally, it reduced hyperexcitability and improved behavioral phenotypes in Hcn1M249L mice, suggesting the feasibility of mechanism-targeted small molecules (though side effects such as tremors need to be balanced) (82). To date, peer-reviewed reports demonstrating robust seizure/behavioral rescue in HCN1-DEE models via HCN1 gene replacement or genome editing remain limited (69).
4.2.2 HCN2 genetic variants and epilepsy
HCN2 channels are among the key HCN channels in the brain. Studies have demonstrated that abnormal HCN2 function is closely associated with epilepsy, especially absence epilepsy (83). First, in Hcn2 knockout (or mutant) animal models, the Ih current in thalamic relay neurons is nearly abolished, and the resting membrane potential is significantly hyperpolarized. This renders neurons more prone to entering a burst oscillation state, ultimately inducing typical ~5 Hz SWD and absence-like seizures (84). Second, human genetic studies have identified rare variants of HCN2 in multiple epilepsy patients, involving two types of mechanisms: GOF and LOF (85, 86). The bidirectional mechanisms of these variants indicate that either a decrease or an increase in HCN2 function alone may disrupt thalamocortical rhythms and trigger epilepsy. Finally, mechanistic studies suggest that in the thalamocortical circuit, the regulation of Ih must be maintained in a “moderate state”: both excessively low Ih (e.g., HCN2 deficiency) and excessively high Ih (e.g., HCN upregulation in certain models) may disrupt rhythmic homeostasis (37). Therefore, HCN2-related epileptogenesis exhibits activity-level (dosage) dependence, brain-region/circuit dependence, and mechanism dependence. Precise regulation of HCN2 channels or individualized interventions targeting mutant forms (such as channel modulators or gene therapy) holds potential clinical significance.
4.2.3 HCN3 genetic variants and epilepsy
The role of HCN3 in epileptogenesis has not been fully investigated to date. One study recruited 298 epilepsy patients, and through Sanger sequencing, three rare heterozygous variants (R457H, P630L, R661Q) in the HCN3 gene were identified. In vitro functional analyses showed that the R457H and R661Q variants significantly reduced cellular current density, which may affect neuronal excitability, while the P630L variant had no effect on ion channel current. Structural analysis indicated that the R457H and R661Q variants decreased the stability of HCN3 channels. Epilepsy was well-controlled after treatment in patients carrying these variants. This study suggests that HCN3 may be a novel candidate gene in the pathogenesis of epilepsy, but additional cases, segregation evidence, and in vivo validation are required (87). In addition, a systematic review summarizing published HCN channelopathy cases reported two postmortem cases carrying rare HCN3 variants (K69R and P630L) that were classified as unclassified/unknown epileptic syndromes and died of SUDEP, raising the possibility of a link between HCN3 variation and SUDEP risk; however, evidence remains extremely limited and requires confirmation in large, well-phenotyped cohorts (37).
4.2.4 HCN4 genetic variants and epilepsy
HCN4 channels play a crucial role in regulating neuronal excitability, rhythmic firing, and synaptic transmission (21, 88, 89), and have been implicated as regulators of epilepsy susceptibility and network-level excitability (90). To date, studies have reported HCN4 variants and abnormal expression implicated in epilepsy subtypes, including idiopathic generalized epilepsy and mTOR-related epileptic syndromes (37, 91–94). In animal models, relevant studies have further support a role for abnormal HCN4 expression in epileptogenesis (88, 95, 96), indicating that HCN4 channels play a significant role in epilepsy and may represent a potential therapeutic target (88).
4.3 Drug-resistant epilepsy
A growing body of evidence from resected human tissue and animal models suggests that acquired abnormalities of HCN channels are associated with drug-resistant focal epilepsies, particularly MTLE-HS. In surgical specimens from human MTLE-HS, HCN1 (and, in some studies, HCN2) mRNA and protein levels in the hippocampus are reduced; subcellular localization analyses further indicate diminished dendritic membrane expression, consistent with decreased dendritic Ih availability/function (76). At the mechanistic level, epileptiform activity or SE can induce rapid endocytosis/mislocalization and downregulated gating of dendritic HCN1 (16, 63), leading to increased dendritic input resistance, abnormal oscillatory activity and temporal integration, thereby promoting network hyperexcitability (referred to as “acquired channelopathy”) (46, 72). This plasticity is finely regulated by channel chaperones and cytoskeletal proteins: Different splice variants of TRIP8b bidirectionally regulate the surface localization and gating of HCN1 (97, 98), while Filamin-A promotes dynamin-dependent endocytosis of HCN1 and restricts Ih (99), suggesting that targeting the trafficking pathway may be a strategy to restore dendritic HCN1. Furthermore, in models of prolonged febrile seizures during development and some acquired epilepsy models, an increased proportion of HCN1/HCN2 heterotetramers and a decreased HCN1/HCN2 ratio have been observed, which alters the kinetics and cAMP sensitivity of Ih. This “subunit reassembly” is thought to contribute to the development of sustained hyperexcitability (100).
In parallel, increased expression and overactivity of the efflux transporter P-glycoprotein (P-gp/ABCB1) has been reported in drug-resistant TLE/MTLE-HS, including upregulation within epileptogenic regions and at the blood–brain barrier (101). PET studies using P-gp substrate tracers further suggest regional P-gp overactivity in pharmacoresistant TLE, supporting an association with the “transporter hypothesis,” whereby enhanced efflux may reduce target-site exposure to some ASMs (102). Taken together, the acquired downregulation/mislocalization of HCN channels (rendering neurons more excitable) and enhanced blood–brain barrier (BBB) efflux (reducing drug exposure) may concurrently drive reduced treatment efficacy in DRE. Future interventions could focus on restoring the expression and localization of dendritic HCN1 (e.g., targeting the TRIP8b/Filamin-A axis), optimizing HCN-targeted modulators, and combining these approaches with transporter modulation strategies.
5 Progress in HCN channel-based epilepsy therapy
5.1 HCN channel agonists
Although no selective HCN channel openers/activators have entered routine clinical practice to date, some marketed ASMs have been reported to enhance the Ih current indirectly or in a context-dependent manner. For example, lamotrigine increases Ih in human layer 2/3 neocortical pyramidal neurons from pharmacoresistant epilepsy patients, decreases input resistance, and reduces EPSP amplitude and temporal summation; the biophysical basis of Ih enhancement may vary across preparations (103). Gabapentin has also been shown to increase Ih amplitude in rat CA1 pyramidal neurons mainly by increasing conductance without significant changes in Ih activation properties or kinetics, and this effect has been proposed to contribute to its antiseizure action (104). In addition, pharmacological elevation of cAMP (e.g., forskolin) can suppress PTZ-induced seizures in rodents; because cAMP facilitates HCN channel opening, these findings are consistent with (but do not by themselves prove) an antiseizure potential of the cAMP–HCN–Ih pathway (105, 106).
However, recent channelopathy studies suggest that “activating HCN channels” is not universally beneficial. Some GOF mutations in HCN1 channels (e.g., M305L) enhance Ih and cause severe epileptic seizures (81); in such patients, even lamotrigine-like drugs may exacerbate symptoms. This indicates that if HCN channel openers are to be developed in the future, strict differentiation should be made based on channel subtypes, brain regions, and mutation backgrounds to achieve precise regulation. Recent molecular biology studies have also explored “targeted modulation” of HCN1 channels using nanobodies, which partially corrected abnormal voltage dependence in vitro (107), providing a proof-of-concept/biophysical basis for “selective HCN modulators.”
5.2 HCN channel inhibitors
HCN channel inhibitors regulate neuronal rhythmic activity and excitability by suppressing the Ih current, but their role in epilepsy is not unidirectional. Early studies suggested that such inhibitors might enhance neuronal excitability, thereby inducing or exacerbating epileptic seizures. This view was partially validated in the Genetic Absence Epilepsy Rats from Strasbourg (GAERS) model: intracerebroventricular injection of a high dose (7 μg) of ZD7288 increased the number of SWD on EEG, indicating that HCN channel inhibition may promote epileptiform activity under certain dose- and time-dependent conditions (108). It should be noted, however, that ZD7288 is not a fully selective HCN blocker and can influence synaptic transmission through off-target actions, which may contribute to its bidirectional effects. In contrast, local application of the Ih blocker ZD7288 within the thalamic ventrobasal (VB) nucleus has been shown to suppress SWD-locked burst firing of VB relay neurons at higher concentrations (2 mM), while no consistent effect on SWD components recorded on the epidural EEG was observed, highlighting the region-specific nature of Ih modulation (109); in TLE models, selective inhibition of HCN channels in the subiculum-anteroventral thalamic nucleus (AV) circuit suppressed epilepsy generalization, demonstrating that its effects depend on differences at the circuit level (108, 110).
Furthermore, HCN channel inhibitors may also exhibit antiepileptic potential in certain types of epilepsy. EC18, a representative HCN4-preferring blocker, significantly reduced network excitability and epileptogenicity in a PTZ-induced convulsion model in wild-type mice, but had no effect in Hcn4 conditional knockout mice—this strongly supports its antiepileptic mechanism via targeting HCN4 channels (88). Another brain-penetrant broad-spectrum HCN channel modulator, Org-34167, has also been shown to modulate neural network excitability and exhibit antiepileptic potential (82); however, high doses can induce motor coordination deficits, suggesting that dose optimization and safety evaluation remain necessary (111). Notably, gabapentin, a traditional anticonvulsant, can also modulate the voltage dependence and kinetic properties of HCN4 channels—this effect may be involved in its antiepileptic mechanism, though direct causal verification is currently lacking (112).
5.3 Other HCN channel-related therapeutic strategies
Under the mechanism-based stratification of DRE, in addition to direct “activation/inhibition” of HCN channels, the Ih current and network synchronization can also be indirectly corrected through multiple levels, including neural networks, co-channels, second messengers, trafficking/endocytosis, and neural circuits: (1) Network neuromodulation—Deep brain stimulation of the anterior nucleus of the thalamus (ANT-DBS) has been shown to reduce seizure frequency in the long term in real-world and follow-up studies (113, 114). Its mechanism is more likely to involve decoupling the limbic-thalamocortical network, thereby potentially affecting HCN/Ih (though direct evidence in humans is lacking for direct upregulation of any specific HCN subtype); (2) Co-channel compensation—Enhancing the dendritic M-current (mediated by Kv7/KCNQ channels) can work with HCN channels to produce a “shunting/damping” effect, reducing dendritic integration and inhibiting abnormal synchronization. The next-generation Kv7 opener XEN1101 demonstrated significant seizure reduction in a Phase IIb randomized controlled trial for adult focal epilepsy and is being evaluated in Phase III (44, 115); (3) Second messenger fine-tuning—The neuromodulator-cAMP axis can induce a positive shift in HCN (particularly HCN2/4) gating. Imaging and mechanistic evidence linking vagus nerve stimulation (VNS) to the locus coeruleus-norepinephrine system provides indirect clinical support for “modulating HCN via cAMP” (21, 116); (4) Trafficking/endocytosis targets—Targeting the TRIP8b-HCN interaction can simultaneously regulate membrane expression and gating (proof-of-concept has been achieved with NUCC-0200590, a small molecule with demonstrated neuronal effects as a proof-of-concept tool) (117, 118); inhibiting Filamin-A-mediated endocytosis of HCN1 offers another approach to “correct acquired channelopathy”; (5) Circuit targeting—In mice, HCN1 expressed in the projection from the subiculum to the ANT promotes the generalization of hippocampal seizures to the thalamocortex. Downregulating or blocking HCN1 in this pathway can alleviate seizures, providing a potential “molecular-circuit” basis for site selection and parameter optimization of DBS/responsive neurostimulation (RNS) (110).
6 Conclusion
HCN channels are key regulators of neuronal excitability and network stability and play important roles in the pathogenesis of epilepsy. In epileptic states, abnormal expression, dysfunction, or gene mutations of HCN channels can induce or exacerbate seizures via Ih dysregulation, disruption of neurotransmitter balance, distortion of E-I balance, and impaired network synchrony. HCN-targeted strategies, including pharmacological modulators, gene-based therapies, and neuromodulation, have shown promising antiepileptic effects in animal models, and some have progressed into early preclinical evaluation.
However, the intrinsic bidirectionality of HCN function poses a major challenge for therapeutic translation. Increasing or decreasing Ih can produce opposite effects: Ih supports both depolarizing rebound and shunting inhibition; presynaptic HCN channels bidirectionally regulate glutamate and GABA release in a circuit- and terminal type-dependent manner; and HCN remodeling and genetic variants include both GOF and LOF changes that are often epileptogenic. In vivo, the same non-selective HCN modulator may suppress seizures in one model or brain region but aggravate them in another. Thus, simple “HCN openers” or “HCN blockers” are unlikely to be universally beneficial and may even worsen seizures in patients whose predominant pathology involves the opposite direction of functional change.
Future work should therefore focus on three directions. First, the development of subtype- and state-selective HCN modulators, guided by structural biology and in silico design, is needed to overcome the limitations of non-specific agents such as ZD7288. Second, CRISPR-based editing and other gene-targeted approaches for HCN channelopathies should be explored, with careful functional stratification of variants and optimization of viral delivery to epileptogenic circuits. Third, integrating multi-omics profiling and long-read sequencing into clinical cohorts may enable robust stratification of epilepsy subtypes and support personalized HCN-targeted interventions for drug-resistant patients.
With the innovative development and deep application of key technologies such as single-cell genomics and precision gene editing in HCN channel research, our understanding of the mechanisms related to HCN channels in epilepsy will continue to deepen. This is expected to overcome translational bottlenecks and provide novel targeted targets for the precise diagnosis and treatment of epilepsy, especially drug-resistant epilepsy.
Author contributions
M-SC: Writing – original draft. PL: Data curation, Investigation, Writing – review & editing. Z-LH: Data curation, Investigation, Writing – review & editing. YL: Writing – review & editing, Data curation, Funding acquisition. J-XZ: Writing – review & editing, Investigation. LJ: Writing – review & editing, Data curation, Validation. H-WW: Funding acquisition, Resources, Supervision, Writing – review & editing. Y-JC: Funding acquisition, Resources, Supervision, Writing – review & editing.
Funding
The author(s) declared that financial support was received for this work and/or its publication. This work was supported by the Hunan Provincial Natural Science Foundation of China (grants nos. 2023JJ50158 and 2025JJ81078), and the “4310” program of clinical medical research of the University of South China (grant no. 20224310NHYCG11).
Conflict of interest
The author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Generative AI statement
The author(s) declared that Generative AI was not used in the creation of this manuscript.
Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
1. GBD Epilepsy Collaborators. Global, regional, and national burden of epilepsy, 1990-2021: a systematic analysis for the global burden of disease study 2021. Lancet Public Health. (2025) 10:e203–27. doi: 10.1016/s2468-2667(24)00302-5
2. Mesraoua, B, Brigo, F, Lattanzi, S, Abou-Khalil, B, al Hail, H, and Asadi-Pooya, AA. Drug-resistant epilepsy: definition, pathophysiology, and management. J Neurol Sci. (2023) 452:120766. doi: 10.1016/j.jns.2023.120766,
3. Perucca, E, Perucca, P, White, HS, and Wirrell, EC. Drug resistance in epilepsy. Lancet Neurol. (2023) 22:723–34. doi: 10.1016/S1474-4422(23)00151-5,
4. Aliyianis, TS, and Winston, GP. The impact of cognitive impairment due to epilepsy on quality of life: what do we know? Epilepsy Res. (2025) 215:107592. doi: 10.1016/j.eplepsyres.2025.107592,
5. Agarwal, A, Bathla, G, Soni, N, Desai, A, Middlebrooks, E, Patel, V, et al. Updates from the international league against epilepsy classification of epilepsy (2017) and focal cortical Dysplasias (2022): imaging phenotype and genetic characterization. AJNR Am J Neuroradiol. (2024) 45:991–9. doi: 10.3174/ajnr.A8178,
6. Epi25 Collaborative. Exome sequencing of 20,979 individuals with epilepsy reveals shared and distinct ultra-rare genetic risk across disorder subtypes. Nat Neurosci. (2024) 27:1864–79. doi: 10.1038/s41593-024-01747-8,
7. Dwivedi, R, Kaushik, M, Tripathi, M, Dada, R, and Tiwari, P. Unraveling the genetic basis of epilepsy: recent advances and implications for diagnosis and treatment. Brain Res. (2024) 1843:149120. doi: 10.1016/j.brainres.2024.149120,
8. Fallico, MJ, Alberca, LN, Enrique, N, Orsi, F, Prada Gori, DN, Martín, P, et al. In silico screening to search for selective sodium channel blockers: when size matters. Brain Res. (2025) 1856:149571. doi: 10.1016/j.brainres.2025.149571,
9. Ng, AC, Chahine, M, Scantlebury, MH, and Appendino, JP. Channelopathies in epilepsy: an overview of clinical presentations, pathogenic mechanisms, and therapeutic insights. J Neurol. (2024) 271:3063–94. doi: 10.1007/s00415-024-12352-x,
10. Marini, C, Porro, A, Rastetter, A, Dalle, C, Rivolta, I, Bauer, D, et al. HCN1 mutation spectrum: from neonatal epileptic encephalopathy to benign generalized epilepsy and beyond. Brain. (2018) 141:3160–78. doi: 10.1093/brain/awy263,
11. Crunelli, V, David, F, Morais, TP, and Lorincz, ML. HCN channels and absence seizures. Neurobiol Dis. (2023) 181:106107. doi: 10.1016/j.nbd.2023.106107,
12. Brennan, GP, Baram, TZ, and Poolos, NP. Hyperpolarization-activated cyclic nucleotide-gated (HCN) channels in epilepsy. Cold Spring Harb Perspect Med. (2016) 6:a022384. doi: 10.1101/cshperspect.a022384,
13. Brown, HF, DiFrancesco, D, and Noble, SJ. How does adrenaline accelerate the heart? Nature. (1979) 280:235–6.
14. Stieber, J, Herrmann, S, Feil, S, Löster, J, Feil, R, Biel, M, et al. The hyperpolarization-activated channel HCN4 is required for the generation of pacemaker action potentials in the embryonic heart. Proc Natl Acad Sci USA. (2003) 100:15235–40. doi: 10.1073/pnas.2434235100,
15. DiFrancesco, D. The role of the funny current in pacemaker activity. Circ Res. (2010) 106:434–46. doi: 10.1161/circresaha.109.208041,
16. Jung, S, Warner, LN, Pitsch, J, Becker, AJ, and Poolos, NP. Rapid loss of dendritic HCN channel expression in hippocampal pyramidal neurons following status epilepticus. J Neurosci. (2011) 31:14291–5. doi: 10.1523/jneurosci.1148-11.2011,
17. Poolos, NP, Rogawski, MA, Delgado-Escueta, AV, Noebels, JL, Avoli, M, and Olsen, RW In: JL Noebels, editor. Jasper's basic mechanisms of the epilepsies. US: National Center for biotechnology information (2012)
18. Oyrer, J, Bleakley, LE, Richards, KL, Maljevic, S, Phillips, AM, Petrou, S, et al. Using a multiplex nucleic acid in situ hybridization technique to determine HCN4 mRNA expression in the adult rodent brain. Front Mol Neurosci. (2019) 12:211. doi: 10.3389/fnmol.2019.00211,
19. Nava, C, Dalle, C, Rastetter, A, Striano, P, de Kovel, CGF, Nabbout, R, et al. De novo mutations in HCN1 cause early infantile epileptic encephalopathy. Nat Genet. (2014) 46:640–5. doi: 10.1038/ng.2952,
20. Roth, FC, and Hu, H. An axon-specific expression of HCN channels catalyzes fast action potential signaling in GABAergic interneurons. Nat Commun. (2020) 11:2248. doi: 10.1038/s41467-020-15791-y,
21. Combe, CL, and Gasparini, S. I(h) from synapses to networks: HCN channel functions and modulation in neurons. Prog Biophys Mol Biol. (2021) 166:119–32. doi: 10.1016/j.pbiomolbio.2021.06.002,
22. Wahl-Schott, C, and Biel, M. HCN channels: structure, cellular regulation and physiological function. Cell Mol Life Sci. (2009) 66:470–94. doi: 10.1007/s00018-008-8525-0,
23. Lee, CH, and MacKinnon, R. Structures of the human HCN1 hyperpolarization-Activated Channel. Cell. (2017) 168:111–120.e11. doi: 10.1016/j.cell.2016.12.023,
24. Peters, CH, Singh, RK, Bankston, JR, and Proenza, C. Regulation of HCN channels by protein interactions. Front Physiol. (2022) 13:928507. doi: 10.3389/fphys.2022.928507,
25. Sartiani, L, Mannaioni, G, Masi, A, Novella Romanelli, M, and Cerbai, E. The hyperpolarization-activated cyclic nucleotide-gated channels: from biophysics to pharmacology of a unique family of ion channels. Pharmacol Rev. (2017) 69:354–95. doi: 10.1124/pr.117.014035,
26. Porro, A, Saponaro, A, Gasparri, F, Bauer, D, Gross, C, Pisoni, M, et al. The HCN domain couples voltage gating and cAMP response in hyperpolarization-activated cyclic nucleotide-gated channels. eLife. (2019) 8. doi: 10.7554/eLife.49672,
27. Wainger, BJ, DeGennaro, M, Santoro, B, Siegelbaum, SA, and Tibbs, GR. Molecular mechanism of cAMP modulation of HCN pacemaker channels. Nature. (2001) 411:805–10. doi: 10.1038/35081088,
28. Zagotta, WN, Olivier, NB, Black, KD, Young, EC, Olson, R, and Gouaux, E. Structural basis for modulation and agonist specificity of HCN pacemaker channels. Nature. (2003) 425:200–5. doi: 10.1038/nature01922,
29. Porro, A, Saponaro, A, Castelli, R, Introini, B, Hafez Alkotob, A, Ranjbari, G, et al. A high affinity switch for cAMP in the HCN pacemaker channels. Nat Commun. (2024) 15:843. doi: 10.1038/s41467-024-45136-y,
30. He, C, Chen, F, Li, B, and Hu, Z. Neurophysiology of HCN channels: from cellular functions to multiple regulations. Prog Neurobiol. (2014) 112:1–23. doi: 10.1016/j.pneurobio.2013.10.001,
31. Nolan, MF, Malleret, G, Lee, KH, Gibbs, E, Dudman, JT, Santoro, B, et al. The hyperpolarization-activated HCN1 channel is important for motor learning and neuronal integration by cerebellar Purkinje cells. Cell. (2003) 115:551–64. doi: 10.1016/s0092-8674(03)00884-5,
32. Santoro, B, Chen, S, Lüthi, A, Pavlidis, P, Shumyatsky, GP, Tibbs, GR, et al. Molecular and functional heterogeneity of hyperpolarization-activated pacemaker channels in the mouse CNS. J Neurosci. (2000) 20:5264–75.
33. Moosmang, S, Biel, M, Hofmann, F, and Ludwig, A. Differential distribution of four hyperpolarization-activated cation channels in mouse brain. Biol Chem. (1999) 380:975–80.
34. Santoro, B, and Shah, MM. Hyperpolarization-activated cyclic nucleotide-gated channels as drug targets for neurological disorders. Annu Rev Pharmacol Toxicol. (2020) 60:109–31. doi: 10.1146/annurev-pharmtox-010919-023356,
35. Seo, H, Seol, MJ, and Lee, K. Differential expression of hyperpolarization-activated cyclic nucleotide-gated channel subunits during hippocampal development in the mouse. Mol Brain. (2015) 8:13. doi: 10.1186/s13041-015-0103-4,
36. Notomi, T, and Shigemoto, R. Immunohistochemical localization of Ih channel subunits, HCN1-4, in the rat brain. J Comp Neurol. (2004) 471:241–76. doi: 10.1002/cne.11039,
37. Kessi, M, Peng, J, Duan, H, He, H, Chen, B, Xiong, J, et al. The contribution of HCN Channelopathies in different epileptic syndromes, mechanisms, modulators, and potential treatment targets: a systematic review. Front Mol Neurosci. (2022) 15:807202. doi: 10.3389/fnmol.2022.807202,
38. Ludwig, A, Zong, X, Jeglitsch, M, Hofmann, F, and Biel, M. A family of hyperpolarization-activated mammalian cation channels. Nature. (1998) 393:587–91.
39. Santoro, B, Liu, DT, Yao, H, Bartsch, D, Kandel, ER, Siegelbaum, SA, et al. Identification of a gene encoding a hyperpolarization-activated pacemaker channel of brain. Cell. (1998) 93:717–29.
40. Ahrari, S, Ozturk, TN, and D'Avanzo, N. Ion behavior in the selectivity filter of HCN1 channels. Biophys J. (2022) 121:2206–18. doi: 10.1016/j.bpj.2022.04.024,
41. Biel, M, Wahl-Schott, C, Michalakis, S, and Zong, X. Hyperpolarization-activated cation channels: from genes to function. Physiol Rev. (2009) 89:847–85. doi: 10.1152/physrev.00029.2008,
42. Pape, HC. Queer current and pacemaker: the hyperpolarization-activated cation current in neurons. Annu Rev Physiol. (1996) 58:299–327.
43. Gasselin, C, Inglebert, Y, and Debanne, D. Homeostatic regulation of h-conductance controls intrinsic excitability and stabilizes the threshold for synaptic modification in CA1 neurons. J Physiol. (2015) 593:4855–69. doi: 10.1113/jp271369,
44. George, MS, Abbott, LF, and Siegelbaum, SA. HCN hyperpolarization-activated cation channels inhibit EPSPs by interactions with M-type K(+) channels. Nat Neurosci. (2009) 12:577–84. doi: 10.1038/nn.2307,
45. Magee, JC. Dendritic hyperpolarization-activated currents modify the integrative properties of hippocampal CA1 pyramidal neurons. J Neurosci. (1998) 18:7613–24.
46. Huang, Z, Walker, MC, and Shah, MM. Loss of dendritic HCN1 subunits enhances cortical excitability and epileptogenesis. J Neurosci. (2009) 29:10979–88. doi: 10.1523/jneurosci.1531-09.2009,
47. Guo, B, Liu, T, Choi, S, Mao, H, Wang, W, Xi, K, et al. Restoring thalamocortical circuit dysfunction by correcting HCN channelopathy in Shank3 mutant mice. Cell Rep Med. (2024) 5:101534. doi: 10.1016/j.xcrm.2024.101534,
48. Yan, Y, Zhu, M, Cao, X, Xu, G, Shen, W, Li, F, et al. Thalamocortical circuit controls neuropathic pain via up-regulation of HCN2 in the ventral posterolateral thalamus. Neurosci Bull. (2023) 39:774–92. doi: 10.1007/s12264-022-00989-5,
49. Lüthi, A, and McCormick, DA. H-current: properties of a neuronal and network pacemaker. Neuron. (1998) 21:9–12.
50. McCormick, DA, and Pape, HC. Properties of a hyperpolarization-activated cation current and its role in rhythmic oscillation in thalamic relay neurones. J Physiol. (1990) 431:291–318.
51. Pape, HC, and McCormick, DA. Noradrenaline and serotonin selectively modulate thalamic burst firing by enhancing a hyperpolarization-activated cation current. Nature. (1989) 340:715–8.
52. Tiryaki, ES, Arslan, G, Günaydın, C, Ayyıldız, M, and Ağar, E. The role of HCN channels on the effects of T-type calcium channels and GABA(a) receptors in the absence epilepsy model of WAG/Rij rats. Pflugers Arch. (2024) 476:337–50. doi: 10.1007/s00424-023-02900-1,
53. Crunelli, V, Cope, DW, and Hughes, SW. Thalamic T-type Ca2+ channels and NREM sleep. Cell Calcium. (2006) 40:175–90. doi: 10.1016/j.ceca.2006.04.022,
54. Nolan, MF, Malleret, G, Dudman, JT, Buhl, DL, Santoro, B, Gibbs, E, et al. A behavioral role for dendritic integration: HCN1 channels constrain spatial memory and plasticity at inputs to distal dendrites of CA1 pyramidal neurons. Cell. (2004) 119:719–32. doi: 10.1016/j.cell.2004.11.020,
55. Huang, H, and Trussell, LO. Presynaptic HCN channels regulate vesicular glutamate transport. Neuron. (2014) 84:340–6. doi: 10.1016/j.neuron.2014.08.046,
56. Huang, Z, Lujan, R, Kadurin, I, Uebele, VN, Renger, JJ, Dolphin, AC, et al. Presynaptic HCN1 channels regulate Cav3.2 activity and neurotransmission at select cortical synapses. Nat Neurosci. (2011) 14:478–86. doi: 10.1038/nn.2757,
57. Cai, W, Liu, S-S, Li, B-M, and Zhang, X-H. Presynaptic HCN channels constrain GABAergic synaptic transmission in pyramidal cells of the medial prefrontal cortex. Biol Open. (2022) 11:8840. doi: 10.1242/bio.058840,
58. Peng, SC, Wu, J, Zhang, DY, Jiang, CY, Xie, CN, and Liu, T. Contribution of presynaptic HCN channels to excitatory inputs of spinal substantia gelatinosa neurons. Neuroscience. (2017) 358:146–57. doi: 10.1016/j.neuroscience.2017.06.046,
59. Fogerson, PM, and Huguenard, JR. Tapping the brakes: cellular and synaptic mechanisms that regulate thalamic oscillations. Neuron. (2016) 92:687–704. doi: 10.1016/j.neuron.2016.10.024,
60. Kim, ED, Wu, X, Lee, S, Tibbs, GR, Cunningham, KP, di Zanni, E, et al. Propofol rescues voltage-dependent gating of HCN1 channel epilepsy mutants. Nature. (2024) 632:451–9. doi: 10.1038/s41586-024-07743-z,
61. Jung, S, Jones, TD, Lugo, JN Jr, Sheerin, AH, Miller, JW, D'Ambrosio, R, et al. Progressive dendritic HCN channelopathy during epileptogenesis in the rat pilocarpine model of epilepsy. J Neurosci. (2007) 27:13012–21. doi: 10.1523/jneurosci.3605-07.2007,
62. Surges, R, Kukley, M, Brewster, A, Rüschenschmidt, C, Schramm, J, Baram, TZ, et al. Hyperpolarization-activated cation current Ih of dentate gyrus granule cells is upregulated in human and rat temporal lobe epilepsy. Biochem Biophys Res Commun. (2012) 420:156–60. doi: 10.1016/j.bbrc.2012.02.133,
63. Jung, S, Bullis, JB, Lau, IH, Jones, TD, Warner, LN, and Poolos, NP. Downregulation of dendritic HCN channel gating in epilepsy is mediated by altered phosphorylation signaling. J Neurosci. (2010) 30:6678–88. doi: 10.1523/jneurosci.1290-10.2010,
64. Wierschke, S, Lehmann, TN, Dehnicke, C, Horn, P, Nitsch, R, and Deisz, RA. Hyperpolarization-activated cation currents in human epileptogenic neocortex. Epilepsia. (2010) 51:404–14. doi: 10.1111/j.1528-1167.2009.02275.x,
65. Cain, SM, Tyson, JR, Jones, KL, and Snutch, TP. Thalamocortical neurons display suppressed burst-firing due to an enhanced Ih current in a genetic model of absence epilepsy. Pflugers Arch. (2015) 467:1367–82. doi: 10.1007/s00424-014-1549-4,
66. Lemes, JA, Rosário, BA, Rocha, SMS, Bandeira, SS, Ribeiro, AM, Vaz, SH, et al. The role of glutamate receptors and transporters in epilepsy: evidence from animal studies. Rev Neurosci. (2025) 36:645–60. doi: 10.1515/revneuro-2024-0173,
67. Zhang, K, Xu, T, Yuan, Z, Wei, Z, Yamaki, VN, Huang, M, et al. Essential roles of AMPA receptor GluA1 phosphorylation and presynaptic HCN channels in fast-acting antidepressant responses of ketamine. Sci Signal. (2016) 9:ra123. doi: 10.1126/scisignal.aai7884,
68. Buss, EW, Lofaro, OM, Barnett, A, Leroy, F, Santoro, B, Siegelbaum, SA, et al. HCN1 hyperpolarization-activated cyclic nucleotide-gated channels enhance evoked GABA release from parvalbumin-positive interneurons. Proc Natl Acad Sci USA. (2024) 121:e2319246121. doi: 10.1073/pnas.2319246121,
69. Bleakley, LE, and Reid, CA. HCN1 epilepsy: from genetics and mechanisms to precision therapies. J Neurochem. (2024) 168:3891–910. doi: 10.1111/jnc.15928,
70. Tsay, D, Dudman, JT, and Siegelbaum, SA. HCN1 channels constrain synaptically evoked Ca2+ spikes in distal dendrites of CA1 pyramidal neurons. Neuron. (2007) 56:1076–89. doi: 10.1016/j.neuron.2007.11.015,
71. Aponte, Y, Lien, CC, Reisinger, E, and Jonas, P. Hyperpolarization-activated cation channels in fast-spiking interneurons of rat hippocampus. J Physiol. (2006) 574:229–43. doi: 10.1113/jphysiol.2005.104042,
72. Bernard, C, Anderson, A, Becker, A, Poolos, NP, Beck, H, and Johnston, D. Acquired dendritic channelopathy in temporal lobe epilepsy. Science (New York, NY). (2004) 305:532–5. doi: 10.1126/science.1097065,
73. Frazzini, V, Cousyn, L, and Navarro, V. Semiology, EEG, and neuroimaging findings in temporal lobe epilepsies. Handb Clin Neurol. (2022) 187:489–518. doi: 10.1016/b978-0-12-823493-8.00021-3,
74. Zhao, T, Cui, X, Zhang, X, Zhao, M, Rastegar-Kashkooli, Y, Wang, J, et al. Hippocampal sclerosis: a review on current research status and its mechanisms. Ageing Res Rev. (2025) 108:102716. doi: 10.1016/j.arr.2025.102716,
75. Jiang, J, Qiu, J, Yin, J, Wang, J, Jiang, X, Yi, Z, et al. Automated detection of hippocampal sclerosis using real-world clinical MRI images. Front Neurosci. (2023) 17:1180679. doi: 10.3389/fnins.2023.1180679,
76. Lin, W, Qin, J, Ni, G, Li, Y, Xie, H, Yu, J, et al. Downregulation of hyperpolarization-activated cyclic nucleotide-gated channels (HCN) in the hippocampus of patients with medial temporal lobe epilepsy and hippocampal sclerosis (MTLE-HS). Hippocampus. (2020) 30:1112–26. doi: 10.1002/hipo.23219,
77. Arnold, EC, McMurray, C, Gray, R, and Johnston, D. Epilepsy-induced reduction in HCN channel expression contributes to an increased excitability in dorsal, but not ventral, hippocampal CA1 neurons. eNeuro. (2019) 6:ENEURO.0036-19.2019. doi: 10.1523/eneuro.0036-19.2019,
78. Bender, RA, Soleymani, SV, Brewster, AL, Nguyen, ST, Beck, H, Mathern, GW, et al. Enhanced expression of a specific hyperpolarization-activated cyclic nucleotide-gated cation channel (HCN) in surviving dentate gyrus granule cells of human and experimental epileptic hippocampus. J Neurosci. (2003) 23:6826–36. doi: 10.1523/jneurosci.23-17-06826.2003,
79. Xie, C, Liu, F, He, H, He, F, Mao, L, Wang, X, et al. Novel HCN1 mutations associated with epilepsy and impacts on neuronal excitability. Front Mol Neurosci. (2022) 15:870182. doi: 10.3389/fnmol.2022.870182,
80. Merseburg, A, Kasemir, J, Buss, EW, Leroy, F, Bock, T, Porro, A, et al. Seizures, behavioral deficits, and adverse drug responses in two new genetic mouse models of HCN1 epileptic encephalopathy. eLife. (2022) 11:826. doi: 10.7554/eLife.70826,
81. Shah, MM. A new HCN1 channelopathy: implications for epilepsy. Brain. (2021) 144:1939–40. doi: 10.1093/brain/awab220,
82. Bleakley, LE, McKenzie, CE, Aung, KP, Soh, MS, Spyrou, J, Forster, IC, et al. Org 34167 rescues voltage dependence of mutant channels and normalizes hyperexcitability in HCN1 epilepsy. Epilepsia. (2025). doi: 10.1111/epi.18585,
83. Houdayer, C, Phillips, AM, Chabbert, M, Bourreau, J, Maroofian, R, Houlden, H, et al. HCN2-associated neurodevelopmental disorders: data from patients and Xenopus cell models. Ann Neurol. (2025) 98:573–89. doi: 10.1002/ana.27277,
84. Ludwig, A, Budde, T, Stieber, J, Moosmang, S, Wahl, C, Holthoff, K, et al. Absence epilepsy and sinus dysrhythmia in mice lacking the pacemaker channel HCN2. EMBO J. (2003) 22:216–24. doi: 10.1093/emboj/cdg032,
85. DiFrancesco, JC, Ragona, F, Murano, C, Frosio, A, Melgari, D, Binda, A, et al. A novel de novo HCN2 loss-of-function variant causing developmental and epileptic encephalopathy treated with a ketogenic diet. Epilepsia. (2023) 64:e222–8. doi: 10.1111/epi.17777,
86. Li, M, Maljevic, S, Phillips, AM, Petrovski, S, Hildebrand, MS, Burgess, R, et al. Gain-of-function HCN2 variants in genetic epilepsy. Hum Mutat. (2018) 39:202–9. doi: 10.1002/humu.23357,
87. Zhao, P, Xiong, H, Kuang, G, Sun, C, Zhang, X, Huang, Y, et al. Analysis of epilepsy-associated variants in HCN3 - functional implications and clinical observations. Epilepsia Open. (2024) 9:2294–305. doi: 10.1002/epi4.13049,
88. Kharouf, Q, Phillips, AM, Bleakley, LE, Morrisroe, E, Oyrer, J, Jia, L, et al. The hyperpolarization-activated cyclic nucleotide-gated 4 channel as a potential anti-seizure drug target. Br J Pharmacol. (2020) 177:3712–29. doi: 10.1111/bph.15088,
89. Zobeiri, M, Chaudhary, R, Blaich, A, Rottmann, M, Herrmann, S, Meuth, P, et al. The hyperpolarization-activated HCN4 channel is important for proper maintenance of oscillatory activity in the Thalamocortical system. Cereb Cortex. (2019) 29:2291–304. doi: 10.1093/cercor/bhz047,
90. Spyrou, J, Escobar, I, Bordey, A, and Reid, CA. Aberrant HCN4 channel expression: impacts on neuronal excitability and implications for epilepsy pathogenesis. Br J Pharmacol. (2025) 182:5693–705. doi: 10.1111/bph.70218,
91. Becker, F, Reid, CA, Hallmann, K, Tae, H‐S, Phillips, AM, Teodorescu, G, et al. Functional variants in HCN4 and CACNA1H may contribute to genetic generalized epilepsy. Epilepsia Open. (2017) 2:334–42. doi: 10.1002/epi4.12068,
92. Rivolta, I, Binda, A, Masi, A, and DiFrancesco, JC. Cardiac and neuronal HCN channelopathies. Pflugers Arch. (2020) 472:931–51. doi: 10.1007/s00424-020-02384-3,
93. Campostrini, G, DiFrancesco, JC, Castellotti, B, Milanesi, R, Gnecchi-Ruscone, T, Bonzanni, M, et al. A loss-of-function HCN4 mutation associated with familial benign myoclonic epilepsy in infancy causes increased neuronal excitability. Front Mol Neurosci. (2018) 11:269. doi: 10.3389/fnmol.2018.00269,
94. Coleman, M, Pinares-Garcia, P, Stephenson, SE, Lee, WS, Kooshavar, D, Mclean, CA, et al. Ectopic HCN4 provides a target biomarker for the genetic Spectrum of mTORopathies. Neurol Genet. (2024) 10:e200135. doi: 10.1212/nxg.0000000000200135,
95. Hsieh, LS, Wen, JH, Nguyen, LH, Zhang, L, Getz, SA, Torres-Reveron, J, et al. Ectopic HCN4 expression drives mTOR-dependent epilepsy in mice. Sci Transl Med. (2020) 12:492. doi: 10.1126/scitranslmed.abc1492,
96. Nguyen, LH, Xu, Y, Nair, M, and Bordey, A. The mTOR pathway genes MTOR, Rheb, Depdc5, Pten, and Tsc1 have convergent and divergent impacts on cortical neuron development and function. eLife. (2024) 12:10. doi: 10.7554/eLife.91010,
97. Huang, Z, Lujan, R, Martinez-Hernandez, J, Lewis, AS, Chetkovich, DM, and Shah, MM. TRIP8b-independent trafficking and plasticity of adult cortical presynaptic HCN1 channels. J Neurosci. (2012) 32:14835–48. doi: 10.1523/jneurosci.1544-12.2012,
98. Bankston, JR, Camp, SS, DiMaio, F, Lewis, AS, Chetkovich, DM, and Zagotta, WN. Structure and stoichiometry of an accessory subunit TRIP8b interaction with hyperpolarization-activated cyclic nucleotide-gated channels. Proc Natl Acad Sci USA. (2012) 109:7899–904. doi: 10.1073/pnas.1201997109,
99. Noam, Y, Ehrengruber, MU, Koh, A, Feyen, P, Manders, EMM, Abbott, GW, et al. Filamin a promotes dynamin-dependent internalization of hyperpolarization-activated cyclic nucleotide-gated type 1 (HCN1) channels and restricts Ih in hippocampal neurons. J Biol Chem. (2014) 289:5889–903. doi: 10.1074/jbc.M113.522060,
100. Brewster, AL, Bernard, JA, Gall, CM, and Baram, TZ. Formation of heteromeric hyperpolarization-activated cyclic nucleotide-gated (HCN) channels in the hippocampus is regulated by developmental seizures. Neurobiol Dis. (2005) 19:200–7. doi: 10.1016/j.nbd.2004.12.015,
101. Han, H, Mann, A, Ekstein, D, and Eyal, S. Breaking bad: the structure and function of the blood-brain barrier in epilepsy. AAPS J. (2017) 19:973–88. doi: 10.1208/s12248-017-0096-2,
102. Feldmann, M, Asselin, MC, Liu, J, Wang, S, McMahon, A, Anton-Rodriguez, J, et al. P-glycoprotein expression and function in patients with temporal lobe epilepsy: a case-control study. Lancet Neurol. (2013) 12:777–85. doi: 10.1016/s1474-4422(13)70109-1,
103. Lehnhoff, J, Strauss, U, Wierschke, S, Grosser, S, Pollali, E, Schneider, UC, et al. The anticonvulsant lamotrigine enhances I(h) in layer 2/3 neocortical pyramidal neurons of patients with pharmacoresistant epilepsy. Neuropharmacology. (2019) 144:58–69. doi: 10.1016/j.neuropharm.2018.10.004,
104. Peng, BW, Justice, JA, Zhang, K, Li, JX, He, XH, and Sanchez, RM. Gabapentin promotes inhibition by enhancing hyperpolarization-activated cation currents and spontaneous firing in hippocampal CA1 interneurons. Neurosci Lett. (2011) 494:19–23. doi: 10.1016/j.neulet.2011.02.045,
105. Sano, M, Seto-Ohshima, A, and Mizutani, A. Forskolin suppresses seizures induced by pentylenetetrazol in mice. Experientia. (1984) 40:1270–1.
106. DiFrancesco, JC, and DiFrancesco, D. Dysfunctional HCN ion channels in neurological diseases. Front Cell Neurosci. (2015) 6:174. doi: 10.3389/fncel.2015.00071,
107. Castelli, R, Sadat Sharifzadeh, A, Porro, A, Saponaro, A, and Moroni, A. Nanobody-mediated modulation of HCN1 channels in epileptic disorders. Biophys J. (2023) 122:163a. doi: 10.1016/j.bpj.2022.11.1034
108. Yavuz, M, Aydın, B, Çarçak, N, and Onat, F. Decreased hyperpolarization-activated cyclic nucleotide-Gated Channel 2 activity in a rat model of absence epilepsy and the effect of ZD7288, an Ih inhibitor, on the spike-and-wave discharges. Pharmacology. (2022) 107:227–34. doi: 10.1159/000520059,
109. Budde, T, Caputi, L, Kanyshkova, T, Staak, R, Abrahamczik, C, Munsch, T, et al. Impaired regulation of thalamic pacemaker channels through an imbalance of subunit expression in absence epilepsy. J Neurosci. (2005) 25:9871–82. doi: 10.1523/jneurosci.2590-05.2005,
110. Fei, F, Wang, X, Xu, C, Shi, J, Gong, Y, Cheng, H, et al. Discrete subicular circuits control generalization of hippocampal seizures. Nat Commun. (2022) 13:5010. doi: 10.1038/s41467-022-32742-x,
111. Pinares-Garcia, P, Spyrou, J, McKenzie, CE, Forster, IC, Soh, MS, Mohamed Syazwan, E, et al. Antidepressant-like activity of a brain penetrant HCN channel inhibitor in mice. Front Pharmacol. (2023) 14:1159527. doi: 10.3389/fphar.2023.1159527,
112. Tae, HS, Smith, KM, Phillips, AM, Boyle, KA, Li, M, Forster, IC, et al. Gabapentin modulates HCN4 channel voltage-dependence. Front Pharmacol. (2017) 8:554. doi: 10.3389/fphar.2017.00554,
113. Kaufmann, E, Peltola, J, Colon, AJ, Lehtimäki, K, Majtanik, M, Mai, JK, et al. Long-term evaluation of anterior thalamic deep brain stimulation for epilepsy in the European MORE registry. Epilepsia. (2024) 65:2438–58. doi: 10.1111/epi.18003,
114. Hu, T, Xie, H, Shan, M, Sang, L, Yang, B, Zhang, Q, et al. Long-term efficacy of anterior nucleus of the thalamus deep brain stimulation in drug-resistant epilepsy: a 5-year multicenter study. BMC Med. (2025) 23:615. doi: 10.1186/s12916-025-04465-5,
115. French, JA, Porter, RJ, Perucca, E, Brodie, MJ, Rogawski, MA, Pimstone, S, et al. Efficacy and safety of XEN1101, a novel Potassium Channel opener, in adults with focal epilepsy: a phase 2b randomized clinical trial. JAMA Neurol. (2023) 80:1145–54. doi: 10.1001/jamaneurol.2023.3542,
116. Berger, A, Vespa, S, Dricot, L, Dumoulin, M, Iachim, E, Doguet, P, et al. How is the norepinephrine system involved in the antiepileptic effects of Vagus nerve stimulation? Front Neurosci. (2021) 15:790943. doi: 10.3389/fnins.2021.790943,
117. Santoro, B, Hu, L, Liu, H, Saponaro, A, Pian, P, Piskorowski, RA, et al. TRIP8b regulates HCN1 channel trafficking and gating through two distinct C-terminal interaction sites. J Neurosci. (2011) 31:4074–86. doi: 10.1523/jneurosci.5707-10.2011,
Keywords: circuits, epilepsy, genetic mechanisms, HCN channels, targeted therapies
Citation: Cai M-S, Liao P, Hu Z-L, Li Y, Zhao J-X, Jin L, Wang H-W and Chen Y-J (2026) Hyperpolarization-activated cyclic nucleotide-gated channels and epilepsy: genetics, circuits, and treatments. Front. Neurol. 16:1744653. doi: 10.3389/fneur.2025.1744653
Edited by:
Miriam Kessi, Central South University, ChinaReviewed by:
Wen Zheng, Central South University, ChinaSiqi Zhang, First Affiliated Hospital of Jinan University, China
Copyright © 2026 Cai, Liao, Hu, Li, Zhao, Jin, Wang and Chen. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Hong-Wei Wang, d2FuZ3JlZGd1YXJkQGZveG1haWwuY29t; Yong-Jun Chen, Y2hlbnlqX2psMjAyM0AxNjMuY29t